INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
Background: Diabetic nephropathy is characterised as either elevated urine albumin excretion or reduced glomerular filtration rate or both.
Aim: The objective of this study is effect of HbA1C and proteinuria in metabolic syndrome of Diabetic nephropathy patients. This approach is used to take precautions to treat metabolic risk factors associated with renal disease.
Result: This study was conducted on 293 subjects of metabolic syndrome of Diabetic nephropathy at Government Medical College and associated groups of hospitals Kota, Rajasthan from September 2019 to August 2021. 293 cases of metabolic syndrome.
Conclusion: Urine dipstick test were found to be positive in 82.6% of metabolic syndrome patients. In our study it has been shown that poor glycaemic control and urine protein dipstick test has an association with metabolic syndrome of diabetic nephropathy.
"EFFECT OF GLYCATED HAEMOGLOBIN AND PROTEINURUIA IN METABOLIC SYNDROME PATIENTS OF DIABETIC NEPHROPATHY", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 5, page no.g73-g75, May-2023, Available :http://www.ijnrd.org/papers/IJNRD2305607.pdf
Downloads:
000118743
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn